Therapeutic Strategies for HER2-Positive Breast Cancer: Exploring Clinical Trial Data and a Treatment Sequence Algorithm

Enhance your knowledge on HER2-positive breast cancer with a live webinar, downloadable slides, an on-demand webcast, and an expert commentary as faculty discuss the most recent data and sequencing of available therapies throughout treatment.

Share

Program Content

Activities

Overview of HER2 and EBC Treatment
Overview of HER2 and Treatment of HER2-Positive Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 28, 2023

Treatment of HER2-Positive MBC
Treatment Selection in HER2-Positive Metastatic Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 28, 2023

Expires: February 27, 2024

Express Pts
ExpressPoints
Therapeutic Strategies for HER2-Positive Breast Cancer: Exploring Clinical Trial Data and a Treatment Sequence Algorithm
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 03, 2023

Expires: March 01, 2024

Activities

Therapeutic Strategies for HER2-Positive Breast Cancer
Therapeutic Strategies for HER2-Positive Breast Cancer: Exploring Clinical Trial Data and a Treatment Sequence Algorithm
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 06, 2023

Expires: April 05, 2024

Activities

HER2-Positive BC: FAQs
Therapeutic Strategies for HER2-Positive Breast Cancer Today: Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2023

Faculty

cover img faculity

Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen Inc.

Additional Information

This program is aligned with specific priorities outlined in the National Strategy for Quality Improvement in Health Care, in particular, making care safer by reducing harm caused in the delivery of care, promoting the most effective prevention and treatment practices for the leading causes of mortality, and promoting effective communication and coordination of care.